Skip to content

The evalustion of fatty liver disease and post-surgical response in patients undergoing bariatric surgery

The magnetic resonance imaging assessment of non-alcoholic fatty liver disease and the evaluation of prognostic factors in patients undergoing bariatric surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003527
Enrollment
75
Registered
2019-02-19
Start date
2018-03-14
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : Bariatric surgery (sleeve gastrectomy): sleeve gastrectomy via laparoscopic approach. Single study arm to compare clinical and metabolic parameters before and after the surgery

Sponsors

Gachon University Gil Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Subjects who understood this clinical study and provided written informed consent to join the study by his or her own decision - Aged 19 or more years or less than 60 years - Subjects who have body mass index =30 kg per square meter and metabolic disease (at least one the following: impaired fasting glucose, hemoglobin A1c 5.7% or more, diabetes, nonalcoholic fatty liver disease, hypertension, hypertriglyceridemia, or metabolic syndrome). - Absence of specific congenital diseases or absence of other chronic diseases and their symptom or signs requiring specific treatment, except for metabolic diseases

Exclusion criteria

Exclusion criteria: - Aged less than 19 years or 60 years or more - Pregnant or lactating women - Body weight >159 kg - Drug abusers - Alcohol consumption (alcohol intake >20 g/day for women; >30 g/day for men) during = 3months in the past 5 years - Psychiatric patients on medical care or medication or subjects with bulimia - Those with AST or ALT level higher than 5 times the upper limit of normal - Those with platelet count < 60,000 per microliter or with prothrombin time longer than 4 seconds or more than the upper limit of normal (14 seconds) - Contraindications to MRI examination - Other specific liver diseases except for NAFLD - Liver cirrhosis with ascites or biliary tract diseases - Medications causing fatty liver (e.g., corticosteroids, tamoxifen, amiodarone, methotrexate and others) within a year - Other systemic diseases seemed to be inappropriate for study participation - Subjects with HIV infection - Subjects with ischemic heart diseases - Subjects with estimated glomerular filtration rates < 45 ml/min/1.73 square meters - Subjects with clinical or subclinical hyperthyroidism or hypothyroidism - Inappropriate for study participation at the discretion of attending physicians

Design outcomes

Primary

MeasureTime frame
Change of liver stiffness measurement (LSM) values measured by MRI before and after bariatric surgery

Secondary

MeasureTime frame
Change of liver fat content measured by MRI and of body weight before and after bariatric surgery;Relationsip between fibrosis grade (0-4) at biopsy during bariatric suregery and MRI-measured LSM change after surgery;Evaluation of determinant for weight loss and the improvement of NAFLD after weight loss

Countries

Korea, Republic of

Contacts

Public ContactDAE HO LEE

Gachon University Gil Medical Center

drhormone@naver.com+82-32-458-2733

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026